


Subject: NCI ETCTN Portfolio of Brain Cancer Trials (June 2018)

Date: Wednesday, June 20, 2018 at 3:14:29 PM Eastern Daylight Time

From: NCI ETCTN Program (sent by NCI ETCTN Program <ET-CTN@mail.nih.gov@mail20.atl71.mcdlv.net>)

To: Massett, Holly (NIH/NCI) [E]



This email provides an up-to-date overview of the National Cancer Institute's Brain Cancer clinical trial portfolio in the ETCTN.

You will find information on:

- Active Brain Cancer trials & recent amendments
- Top accruing sites to Brain Cancer trials
- Brain Cancer protocols activating soon
- Brain Cancer protocols in development
- Notes/Updates from NCI CTEP

[Click here to see all ETCTN trials by disease type](#)

Active Brain Cancer Trials & Recent Amendments

Document Title: [\(9952\) Phase 1 Trial to Determine the Recommended Phase 2 Dose \(RP2D\) of VX-970 When Combined with Whole Brain Radiotherapy \(WBRT\) in Patients with Brain Metastases from Non-Small Cell Lung Cancer \(NSCLC\).](#)

Accrual Goal: 46
Planned Accrual Rate: 6/mo
Current Accrual: 5

Principal Investigator: Mohindra, Pranshu
Principal Investigator Email: pmohindra@som.umaryland.edu
Lead Organization Name: Mayo Clinic Cancer Center LAO (LAO-MN026)

Document Title: [\(9979\) Phase 1 and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-](#)

Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases

Accrual Goal: 47

Planned Accrual Rate: 2/mo

Current Accrual: 2

Principal Investigator: Mohindra, Pranshu

Principal Investigator Email: pmohindra@som.umaryland.edu

Lead Organization Name: Mayo Clinic Cancer Center LAO
(LAO-MN026)

Document Title: (10042) A Phase II Trial of AZD9291 (Osimertinib) with or without Bevacizumab in Patients with EGFR Mutation Positive NSCLC and Brain Metastases

Accrual Goal: 98

Planned Accrual Rate: 3/mo

Current Accrual: 0

Principal Investigator: Goldberg, Sarah B.

Principal Investigator Email: sarah.goldberg@yale.edu

Lead Organization Name: Yale University Cancer Center LAO
(LAO-CT018)

Recent amendments & updates: Trial is once again open to accrual.

Document Title: (10067) A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients with Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy

Accrual Goal: 70

Planned Accrual Rate: 7/mo

Current Accrual: 30

Principal Investigator: Arrillaga-Romany, Isabel

Principal Investigator Email: iarrillaga@mgh.harvard.edu

Lead Organization Name: Dana-Farber - Harvard Cancer Center LAO
(LAO-MA036)

Top Accruing Sites to Brain Cancer Trials

Massachusetts General Hospital Cancer Center
UC San Diego Moores Cancer Center
Ohio State University Comprehensive Cancer Center

A big thank you to our top accruing sites across active

Brain Cancer trials!

Brain Cancer Protocols Activating Soon

Document Title: (10218) A Phase Ib Trial of CB-839 in Combination with Radiation Therapy and Temozolomide in Patients with IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma

Expected Activation

Date: 2/8/2019

Principal Investigator: Kizilbash, Sani Haider

Principal Investigator Email: kizilbash.sani@mayo.edu

Lead Organization Name: Mayo Clinic Cancer Center LAO (LAO-MN026)

Brain Cancer Protocols in Development

Document Title: (10186) A Phase I/II Study Hypofractionated Radiation Therapy in Combination with Nivolumab and Ipilimumab for Recurrent High-Grade Radiation-Refractory Meningioma

Expected Activation Date:

9/7/2018

Principal Investigator: Huang, Jiayi

Principal Investigator Email: jiayi.huang@wustl.edu

Lead Organization Name: Duke University - Duke Cancer Institute
LAO (LAO-NC010)

Document Title: (10220) Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 in Patients with NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1 and LKB1 Aberrant Tumors

Expected Activation

Date: 2/8/2019

Principal Investigator: Subbiah, Vivek

Principal Investigator Email: vsubbiah@mdanderson.org

Lead Organization Name: University of Texas MD Anderson Cancer
Center LAO (LAO-TX035)

Notes/Updates from NCI CTEP

Congratulations to Dr. Jeff Moscow on his appointment to Branch Chief of the Investigational Drug Branch (IDB) in NCI's Cancer Therapy Evaluation Program (CTEP) in the Division of Cancer Treatment and Diagnosis (DCTD).

The ETCTN competitive renewal grant was approved by NCI to go to the Board of Scientific Advisors (BSA) for review at their upcoming meeting on June 26, 2018.

Check out NCI-CTEP's Twitter account! @NCICTEP_ClinRes

Interested in receiving newsletters for other types of cancer clinical trials? [Click here.](#)

Questions or feedback? Email us at ET-CTN@mail.nih.gov



This email was sent to massetth@mail.nih.gov
[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)
National Cancer Institute · 9609 Medical Center Dr. · Rockville, MD 20852 · USA

MailChimp